Previous close | 74.45 |
Open | 74.45 |
Bid | 74.46 x 900 |
Ask | 74.48 x 800 |
Day's range | 74.39 - 75.18 |
52-week range | 65.00 - 81.44 |
Volume | |
Avg. volume | 9,026,745 |
Market cap | 158.165B |
Beta (5Y monthly) | 0.42 |
PE ratio (TTM) | 25.22 |
EPS (TTM) | 2.95 |
Earnings date | 27 Apr 2023 |
Forward dividend & yield | 2.28 (3.06%) |
Ex-dividend date | 05 Jan 2023 |
1y target est | 82.49 |
Bristol Myers' Sotyktu recently moved one step closer to its first approval in the European Union.
Shares in pharmaceutical company Bristol Myers Squibb (NYSE: BMY) are up a little more than 11% over the past year. The company posted third-quarter revenue of $11.2 billion, a decrease of 3%, with one culprit being the loss of exclusivity for one of its blockbuster drugs, Revlimid. The blood cancer therapy reported sales of $2.4 billion, down 28% year over year.
Bristol-Myers Squibb ( NYSE:BMY ) Full Year 2022 Results Key Financial Results Revenue: US$46.2b (flat on FY 2021). Net...